Clinical trial · Observational
Nerve Changes in Patients Who Are Undergoing Chemotherapy or Biological Therapy for Cancer
Characterization of Chemotherapy/Biotherapy-Induced Peripheral Neuropathy: Refinement of Clinical Measures
NCT00281853CI-TRIAL-00003539completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Learning about the effects of chemotherapy and biological therapy on nerve function may help doctors plan treatment and help patients live more comfortably. PURPOSE: This clinical trial is studying peripheral neuropathy in patients who are receiving chemotherapy or biological therapy for cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neurotoxicity | — | UNRESOLVED | — |
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| management of therapy complications | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Hearing as measured by the Weber test and the Rinne test at baseline, and then weeks 4, 8, and 12 during study treatment
- timeFrame
- baseline, and then weeks 4, 8, and 12 during study treatment
- measure
- Vibratory sensation as measured by tuning fork at baseline, and then weeks 4, 8, and 12 during study treatment
- timeFrame
- baseline, and then weeks 4, 8, and 12 during study treatment
- measure
- Blood pressure changes at baseline, and then weeks 4, 8, and 12 during study treatment
- timeFrame
- baseline, and then weeks 4, 8, and 12 during study treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
- Maximum age
- 85 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed diagnosis of cancer * Scheduled to be treated with 1 of the following agents: * Cisplatin/paclitaxel combination * Biologic therapy with high-dose interferon alfa PATIENT CHARACTERISTICS: * Normal vision OR vision corrected with glasses or contact lenses * No diseases or disorders reducing peripheral nerve function, including any of the following: * Diabetes mellitus * HIV/AIDS * Uremia * Spinal injuries * Alcoholism * CNS problems * No hearing impairment PRIOR CONCURRENT THERAPY: * No prior biologic therapy or neurotoxic chemotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.